RT Journal Article
SR Electronic
T1 Nanopore Metagenomic Sequencing for Detection and Characterization of SARS-CoV-2 in Clinical Samples
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.08.13.21261922
DO 10.1101/2021.08.13.21261922
A1 Gauthier, Nick P.G.
A1 Nelson, Cassidy
A1 Bonsall, Michael B.
A1 Locher, Kerstin
A1 Charles, Marthe
A1 MacDonald, Clayton
A1 Krajden, Mel
A1 Chorlton, Samuel D.
A1 Manges, Amee R.
YR 2021
UL http://medrxiv.org/content/early/2021/08/23/2021.08.13.21261922.abstract
AB The COVID-19 pandemic has underscored the need for rapid novel diagnostic strategies to detect and characterize pathogens from clinical specimens. The MinION sequencing device allows for rapid, cost-effective, high-throughput sequencing; useful features for translation to clinical laboratory settings. Metagenomic Next-Generation Sequencing (mNGS) approaches provide the opportunity to examine the entire genomic material of a sample; allowing for detection of emerging and clinically relevant pathogens that may be missed in targeted assays. Here we present a pilot study on the performance of Sequence-Independent Single Primer Amplification (SISPA) to amplify RNA randomly for the detection and characterization of SARS-CoV-2. We designed a classifier that corrects for barcode crosstalk between specimens. Our assay yielded 100% specificity overall and 95.2% sensitivity for specimens with a RT-qPCR cycle threshold value less than 30. We assembled 10 complete (>95% coverage at 20x depth), and one near-complete (>80% coverage at 20x depth) genomes from 20 specimens that were classified as positive by mNGS. We characterized these genomes through phylogenetic analysis and found that 10/11 specimens from British Columbia had a closest relative to another British Columbian specimen. Of five samples that we had both assembled genomes, as well as Variant of Concern (VOC) PCR results, we found 100% concordance between these results. Additionally, our assay was able to distinguish between the Alpha and Gamma variants, which was not possible with our VOC PCR technique. This study supports future work examining the broader feasibility of SISPA as a diagnostic strategy for the detection and characterization of viral pathogens.Competing Interest StatementSDC holds equity in BugSeq Bioinfomatics Inc.Funding StatementExternal funding for this project was provided by the Berkeley Existential Risk InitiativeAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This project has been approved by the University of British Columbia research ethics board, as well as the University of Oxford Central University Research Ethics CommitteeAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRaw FASTQ data has been uploaded to NCBI Bioproject Accession PRJNA752146, analysis code provided in attached gitlab link. https://gitlab.com/bugseq/sars-cov-2-nanopore-mngs-performance